Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Rosenberg

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Acta Obstetricia Et Gynecologica Scandinavica|March 15, 2021
Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer-A Swedish Gynecologic Cancer Group (SweGCG) studyBjörg Jónsdóttir, Janusz Marcickiewicz, Christer Borgfeldt, et al.
BMC Cancer|June 3, 2021
Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) studyChrister Borgfeldt, Erik Holmberg, Janusz Marcickiewicz, et al.
Gynecologic Oncology|September 4, 2019
Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group StudyMaria Bjurberg, Erik Holmberg, Christer Borgfeldt, et al.
Environmental Pollution (Barking, Essex : 1987)|July 22, 2008
Variation of MCPA, metribuzine, methyltriazine-amine and glyphosate degradation, sorption, mineralization and leaching in different soil horizonsCarsten S Jacobsen, Peter van der Keur, Bo V Iversen, et al.
British Journal of Cancer|January 25, 2017
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)Kristina Lindemann, Emma Gibbs, Elisabeth Åvall-Lundqvist, et al.
Gynecologic Oncology|February 14, 2021
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG studyPernilla Dahm-Kähler, Erik Holmberg, Mikael Holtenman, et al.
Acta Oncologica (Stockholm, Sweden)|August 3, 2019
Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) studyKarin Stålberg, Maria Bjurberg, Christer Borgfeldt, et al.
Medical Oncology (Northwood, London, England)|June 27, 2014
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS studyJalid Sehouli, Klaus Pietzner, Pauline Wimberger, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studiesThomas Hogberg, Mauro Signorelli, Carlos Freire de Oliveira, et al.
International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Acta Obstetricia Et Gynecologica Scandinavica|March 15, 2021
Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer-A Swedish Gynecologic Cancer Group (SweGCG) studyBjörg Jónsdóttir, Janusz Marcickiewicz, Christer Borgfeldt, et al.
BMC Cancer|June 3, 2021
Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) studyChrister Borgfeldt, Erik Holmberg, Janusz Marcickiewicz, et al.
Gynecologic Oncology|September 4, 2019
Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group StudyMaria Bjurberg, Erik Holmberg, Christer Borgfeldt, et al.
Environmental Pollution (Barking, Essex : 1987)|July 22, 2008
Variation of MCPA, metribuzine, methyltriazine-amine and glyphosate degradation, sorption, mineralization and leaching in different soil horizonsCarsten S Jacobsen, Peter van der Keur, Bo V Iversen, et al.
British Journal of Cancer|January 25, 2017
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)Kristina Lindemann, Emma Gibbs, Elisabeth Åvall-Lundqvist, et al.
Gynecologic Oncology|February 14, 2021
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG studyPernilla Dahm-Kähler, Erik Holmberg, Mikael Holtenman, et al.
Acta Oncologica (Stockholm, Sweden)|August 3, 2019
Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) studyKarin Stålberg, Maria Bjurberg, Christer Borgfeldt, et al.
Medical Oncology (Northwood, London, England)|June 27, 2014
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS studyJalid Sehouli, Klaus Pietzner, Pauline Wimberger, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studiesThomas Hogberg, Mauro Signorelli, Carlos Freire de Oliveira, et al.
International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Pageof 5